Chemotherapy Group, N (% of 2,081 in Cohort)	Regimen	Number of Patients in Regimen (% of Chemotherapy Group)
Doublets, 1,088 (52.3)	Carboplatin + paclitaxel	739 (67.9)
	Carboplatin + gemcitabine	171 (15.7)
	Cisplatin + etoposide	103 (9.5)
	Cisplatin + gemcitabine	47 (4.3)
	Cisplatin + vinorelbine	28 (2.6)
Pemetrexed-based regimens, 279 (13.4)	Carboplatin + pemetrexed	155 (55.6)
	Cisplatin + pemetrexed	83 (29.7)
	Pemetrexed	41 (14.7)
Pemetrexed + bevacizumab-based combinations, 38 (1.8)	Bevacizumab + carboplatin + pemetrexed	21 (55.3)
	Bevacizumab + cisplatin + pemetrexed	13 (34.2)
	Bevacizumab + pemetrexed	4 (10.5)
Bevacizumab-based regimens, 167 (8.0)	Bevacizumab + carboplatin + paclitaxel	140 (83.8)
	Bevacizumab + carboplatin + gencitabine	13 (7.8)
	Bevacizumab	10 (6.0)
	Bevacizumab + cisplatin + gemcitabine	2 (1.2)
	Bevacizumab + gemcitabine	2 (1.2)
Singlets, 114 (5.5)	Gemcitabine	38 (33.3)
	Vinorelbine	37 (32.5)
	Paclitaxel	28 (24.6)
	Docetaxel	11 (9.6)
Tyrosine-kinase inhibitors, 395 (19.0)	Erlotinib	395 (100.0)